Related Experiment Video

Updated: May 15, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Dacomitinib, a new therapy for the treatment of non-small cell lung cancer

Christina Brzezniak1, Corey A Carter, Giuseppe Giaccone

  • 1Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889, USA.

Expert Opinion on Pharmacotherapy
|January 9, 2013
PubMed
Abstract

Insights

Second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitors (TKIs), like dacomitinib, show promise for advanced non-small cell lung cancer (NSCLC). Dacomitinib is effective as initial treatment and may overcome resistance to earlier therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Advanced or metastatic non-small cell lung cancer (NSCLC) has a poor prognosis with limited treatment options.
  • First-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective but resistance develops.
  • Second-generation irreversible TKIs aim to overcome resistance and prolong targeted therapy benefits.

Purpose of the Study:

  • Review ongoing research on the second-generation irreversible TKI, dacomitinib.
  • Evaluate the efficacy of dacomitinib in advanced or metastatic NSCLC.
  • Explore dacomitinib's potential in overcoming EGFR TKI resistance.

Main Methods:

  • Literature review of published and ongoing research on dacomitinib.
  • Analysis of dacomitinib's efficacy in NSCLC patients.
  • Examination of preclinical data regarding dacomitinib's activity against resistant mutations.

Main Results:

  • Dacomitinib demonstrates efficacy in NSCLC patients as both initial therapy and after first-generation TKI failure.
  • Preclinical data suggest dacomitinib may be effective against the T790M resistance mutation.
  • Ongoing investigations explore dacomitinib's role in delaying resistance and in combination therapies.

Conclusions:

  • Dacomitinib shows effectiveness in NSCLC, including in patients resistant to first-generation TKIs.
  • The drug holds potential for treating tumors with the T790M mutation.
  • Further research is investigating dacomitinib's ability to delay resistance and its use in combination strategies.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...